Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly Explores New R&D Cooperation Model In

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly, one of the first international drug companies to develop large-scale R&D activities in China, continues to explore new R&D cooperation models aimed at enhancing partnerships

You may also be interested in...



Coronavirus Update: Lilly Begins Clinical Trial Of Antibody Therapy

EMA Addresses Calls To Publish COVID-19 Clinical Data

The European Medicines Agency’s clinical data publication policy is on hold, but calls are growing for the regulator to start publishing trial data for COVID-19 treatments and vaccines as soon as they are authorized in the EU.

COVID And Beyond: China Urged To Address Chronic Disease, Improve Access

Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.

UsernamePublicRestriction

Register

LL1132530

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel